Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis

참고문헌 (6)

1. Selva-O’Callaghan A, "Classification and management of adult inflammatory myopathies", Lancet Neurol, 17, pp.816~828 (2018)
2. Fiorentino D, "The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study", J Am Acad Dermatol, 65, pp.25~34 (2011)
3. Greenberg SA, "Dermatomyositis and type 1 interferons", Curr Rheumatol Rep, 12, pp.198~203 (2010)
4. Abe Y, "Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis", Rheumatology(Oxford), 56, pp.1492~1497 (2017)
5. Hughes M, "Digital ulcers in systemic sclerosis", Rheumatology(Oxford), 56, pp.14~25 (2017)
6. Motegi S, "Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis : a prospective, case series study", J Dermatol, 43, pp.56~62 (2016)

관련 논문AI추천